Table 2

Risk of MACE among patients receiving HZ vaccination compared with no vaccination and head-to-head comparison of Shingrix versus Zostavax

	Exposure group		Comparison
	n	No. of event	n	No. of event	HR (95% CI)	P value
Any HZ vaccine versus no HZ vaccine (model 1 matched population)
MACE	45 958	3474	45 958	4060	0.76 (0.72 to 0.79)	<0.001
Coronary artery disease	45 958	1902	45 958	2331	0.73 (0.69 to 0.78)	<0.001
Stroke	45 958	1863	45 958	2116	0.79 (0.74 to 0.84)	<0.001
All-cause mortality	45 958	2793	45 958	4794	0.54 (0.52 to 0.57)	<0.001
Shingrix versus no HZ vaccine (model 2 matched population)
MACE	14 142	858	14 142	1294	0.84 (0.76 to 0.91)	<0.001
Coronary artery disease	14 142	468	14 142	770	0.78 (0.69 to 0.88)	<0.001
Stroke	14 142	445	14 142	650	0.87 (0.77 to 0.99)	0.035
All-cause mortality	14 142	569	14 142	1561	0.53 (0.48 to 0.58)	<0.001
Zostavax versus no HZ vaccine (model 3 matched population)
MACE	11 285	1674	11 285	1030	0.81 (0.75 to 0.88)	<0.001
Coronary artery disease	11 285	910	11 285	616	0.72 (0.65 to 0.80)	<0.001
Stroke	11 285	952	11 285	530	0.90 (0.81 to 1.01)	0.065
All-cause mortality	11 285	1496	11 285	1203	0.58 (0.53 to 0.62)	<0.001
Shingrix versus Zostavax (model 4 matched population)
MACE	10 505	615	10 505	1574	1.09 (0.98 to 1.21)	0.104
Coronary artery disease	10 505	335	10 505	859	1.16 (1.01 to 1.34)	0.036
Stroke	10 505	310	10 505	900	0.96 (0.83 to 1.11)	0.582
All-cause mortality	10 505	378	10 505	1400	0.99 (0.87 to 1.12)	0.824

The p-value is derived from the log-rank test.
Any HZ vaccine, Shingrix or Zostavax; HZ, herpes zoster; MACE, major adverse cardiovascular events.